Shanghai Yuguan Biotech Co., Ltd.（delonix Bioworks)

This early-stage study aims to test the safety and immune response of a new vaccine (DX-104) designed to protect against meningitis B. It will involve 30 healthy adults aged 18-50, who will receive three shots over six months. The new vaccine's safety and ability to trigger prote…